(Q40256702)

18 September 2017

title

Dengue vaccine efficacy trial: does interference cause failure? (English)

1 reference

18 September 2017

0 references

4

Suresh Mahalingam

1 reference

18 September 2017

2

Navin Khanna

1 reference

Sathyamangalam Swaminathan

18 September 2017

series ordinal

1

object named as

Sathyamangalam Swaminathan

1 reference

18 September 2017

Belinda Herring

3

1 reference

18 September 2017

publication date

1 March 2013

1 reference

Lancet Infectious Diseases

18 September 2017

published in

1 reference

18 September 2017

volume

13

1 reference

18 September 2017

issue

3

1 reference

18 September 2017

page(s)

191-192

1 reference

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970028-8

7 January 2021

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970028-8

7 January 2021

Evaluation of interferences between dengue vaccine serotypes in a monkey model.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970028-8

7 January 2021

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970028-8

7 January 2021

Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970028-8

7 January 2021

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970028-8

7 January 2021

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970028-8

7 January 2021

Epidemiologic studies on Dengue in Santiago de Cuba, 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970028-8

7 January 2021

Dengue vaccine development: a 75% solution?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970028-8

7 January 2021

10.1016/S1473-3099(13)70028-8

Identifiers

DOI

1 reference

18 September 2017

1 reference